Search results for "Prostatic neoplasm"

showing 10 items of 285 documents

Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically …

2009

OBJECTIVE To evaluate the expression of urokinase-plasminogen-activator receptor (uPA-R) in disseminated tumour cells (DTC) in bone marrow (BM) and peripheral blood (PB) of patients with clinically localized prostate cancer before radical prostatectomy (RP), and to assess the associations with pathological variables and prognosis. PATIENTS AND METHODS In all, 52 patients (47 with clinically localized cancer and five with benign prostatic hyperplasia, BPH, as controls) were prospectively enrolled. BM and PB samples were drawn before surgery. DTC were enriched using a commercial system, cytokeratin (CK) 8/18 was used to detect DTC, and uPA-R expression was detected by dual-immunostaining of t…

Malemedicine.medical_specialtyPathologyUrologyReceptor expressionmedicine.medical_treatmentGastroenterologyReceptors Urokinase Plasminogen ActivatorCytokeratinProstate cancerBone MarrowInternal medicinemedicineBiomarkers TumorHumansAgedProstatectomybusiness.industryProstatectomyCancerProstatic NeoplasmsHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseNeoplastic Cells CirculatingPrognosisImmunohistochemistryUrokinase receptormedicine.anatomical_structureLymphatic MetastasisBone marrowNeoplasm Recurrence LocalbusinessEpidemiologic MethodsBJU international
researchProduct

Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single‐centre open‐label uncontrolled trial

2020

Phosphodiesterase-5 inhibitors are the first-line therapy for erectile dysfunction (ED) after radical prostatectomy (RP). This single-centre open-label uncontrolled study evaluated the efficacy and safety of the new sildenafil orodispersible film (ODF) in ED treatment after RP. Sildenafil 100 mg ODF was administered twice a week for 3 months to patients under 75 years of age, with a Framingham cardiovascular risk score < 20% and a pre-operative International Index of Erectile Function (IIEF)-5 score ≥ 17, who had undergone open RP between 2016 and 2018. Erectile function was assessed pre-operatively, post-operatively and after treatment through the IIEF-5 score, the Sexual Encounter Prof…

Malemedicine.medical_specialtyPercentileSildenafilUrologymedicine.medical_treatment030232 urology & nephrologyUrologyUncontrolled Studyprostatic neoplasmsSildenafil Citrate03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyErectile DysfunctiontherapeuticsHumansMedicineAdverse effectProstatectomy030219 obstetrics & reproductive medicineFramingham Risk Scorebusiness.industryProstatectomyPenile ErectionOrodispersible filmGeneral MedicinePhosphodiesterase 5 Inhibitorsmedicine.diseaseTreatment OutcomeErectile dysfunctionchemistrybusinessAndrologia
researchProduct

Inhibition of Platelet Aggregation Caused by Estrogen Treatment in Patients with Carcinoma of the Prostate

1975

Platelet aggregation is increased in patients with carcinoma of the prostate treated with estrogens. Hence, these patients have a high incidence of cardiovascular and thromboembolic diseases. Platelet aggregation has been tested with the platelet aggregation test. It was inhibited by administration of 500 mg. acetylsalicylic acid twice daily. An aggregation inhibiting effect has been found in all 38 patients. To reduce the excess hazards of cardiovascular complications of estrogens in treating carcinoma of the prostate acetylsalicylic acid is recommended as an adjunct therapy.Estrogen therapy for prostatic carcinoma may lead to the development of cardiovascular complications, such as thromb…

Malemedicine.medical_specialtyPlatelet Aggregationmedicine.drug_classUrologyPopulationPharmacologyPlatelet AdhesivenessProstateInternal medicineCarcinomaHumansEndocrine systemMedicineCastrationeducationDiethylstilbestroleducation.field_of_studyAspirinEstradiolbusiness.industryGenitourinary systemProstatic NeoplasmsCancerEstrogensmedicine.diseaseEndocrinologymedicine.anatomical_structureEstrogenbusinessHormoneJournal of Urology
researchProduct

Alterations of peripheral testosterone metabolism after induced hypoprolactinemia in patients with prostatic carcinoma

1979

In 12 patients with advanced prostatic carcinoma the effect of bromocriptine-induced hypoprolactinemia on the peripheral androgen metabolism was investigated after 3H-testosterone injection under conditions that each individual served as his own control. After a 5-day significant prolactin suppression, the elimination of 3H-label 1 h after testosterone injection was about 45% and equal to pre-bromocriptine values. The recovery of dihydrotestosterone separated by silica gel T.L.C., however, was significantly augmented, resulting in a marked decrease of the testosterone/dihydrotestosterone ratio from 12.2 to 6.3. This induced 5alpha-reductase activity after prolactin suppression is in accorda…

Malemedicine.medical_specialtyPopulationAndrologyProstateInternal medicineDrug DiscoverymedicineCarcinomaHumansTestosteroneeducationBromocriptineGenetics (clinical)TestosteroneAgededucation.field_of_studybusiness.industryProstatic NeoplasmsGeneral Medicinemedicine.diseaseProlactinProlactinHypoprolactinemiaEndocrinologymedicine.anatomical_structureDihydrotestosteroneMolecular MedicineDeficiency DiseasesbusinessHormonemedicine.drugKlinische Wochenschrift
researchProduct

Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Large Multicenter Cohort Study.

2020

Focal therapy (FT) with its favorable side-effect profile represents an option between active surveillance and traditional whole-gland treatment in localized prostate cancer (PCa). Consensus statements recommend eligibility criteria based on magnetic resonance imaging (MRI)-targeted and systematic combination biopsy.To estimate the future potential of FT by analyzing the number of men eligible for FT among all men with biopsy-proven PCa and to judge the potential of different energy sources.Consensus criteria on FT were analyzed. Patients with biopsy-proven PCa from six tertiary referral hospitals and one outpatient practice in Germany had received a software-based combination biopsy. Men w…

Malemedicine.medical_specialtyProstate biopsyUrologyBiopsy030232 urology & nephrologyCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineProstateBiopsyMedicineHumansmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsMagnetic resonance imagingProstate-Specific Antigenmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structure030220 oncology & carcinogenesisProstate neoplasmRadiologybusinessEnergy sourceCohort studyEuropean urology focus
researchProduct

Outcome of radical prostatectomy for incidental carcinoma of the prostate

2009

OBJECTIVE To evaluate a contemporary series of patients with incidental prostate cancer detected by transurethral resection of the prostate (TURP) and undergoing radical prostatectomy (RP). PATIENTS AND METHODS Between 1998 and 2004, 1931 patients had TURP for obstructive voiding symptoms and suspected BPH. Incidental prostate cancer was found in 104 (5.4%); 26 of these patients had a RP. The pathological staging and treatment of these patients were reviewed retrospectively and the follow-up results obtained. RESULTS Of the 26 patients who had RP, 17 had T1a and nine had T1b carcinoma of the prostate. After RP, six (35%) in the T1a group had no residual tumour (pT0) and 11 (65%) had pT2 can…

Malemedicine.medical_specialtyProstate biopsyUrologymedicine.medical_treatmentPathological stagingProstatic HyperplasiaUrologyurologic and male genital diseasesProstate cancerProstatemedicineHumansAgedTransurethral resection of the prostateProstatectomyIncidental Findingsmedicine.diagnostic_testbusiness.industryProstatectomyProstatic NeoplasmsCancerMiddle AgedProstate-Specific Antigenmedicine.diseaseTreatment Outcomemedicine.anatomical_structureHormonal therapyEpidemiologic MethodsbusinessProstatismBJU International
researchProduct

Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.

2008

We determined indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.Of 316 cystoprostatectomy specimens concomitant prostate cancer was diagnosed in 21.5%. Prostate cancer was diagnosed preoperatively in 24% of cases (evident prostate cancer), 32% were suspicious for prostate cancer but no biopsy was done (suspected prostate cancer) and in 44% prostate cancer was incidental. Patients were stratified into probability groups of intermediate/high risk prostate cancer by digital rectal examination and prostate specific antigen. The incidence of unfavorable histopathology was determined in each group.Of prostate cancers 85% were organ c…

Malemedicine.medical_specialtyProstate biopsyUrologymedicine.medical_treatmentUrologyCystectomyRisk AssessmentCystoprostatectomyCohort StudiesProstate cancerProstatePredictive Value of TestsPreoperative CaremedicineHumansAgedNeoplasm StagingRetrospective StudiesAged 80 and overProstatectomyCarcinoma Transitional CellUrinary bladderBladder cancermedicine.diagnostic_testbusiness.industryBiopsy NeedleProstateCancerProstatic NeoplasmsNeoplasms Second PrimaryMiddle AgedProstate-Specific Antigenmedicine.diseaseCombined Modality TherapyImmunohistochemistrySurvival AnalysisProstate-specific antigenmedicine.anatomical_structureTreatment OutcomeUrinary Bladder NeoplasmsbusinessFollow-Up StudiesThe Journal of urology
researchProduct

Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy

2015

INTRODUCTION Aim of the study is to evaluate the impact of Cho-PET/CT in decision-making strategy of patients with localized prostate cancer (PC) eligible to definitive radiotherapy (RT). MATERIALS AND METHODS Sixty patients Cho-PET/CT before RT were prospectively enrolled. All patients were treated with volumetric modulated arc therapy with simultaneous integrated boost in 28 fractions. Androgen deprivation therapy was prescribed according to National Comprehensive Cancer Network (NCCN) risk classification. Therapeutic strategy based on the Cho-PET/CT evaluation was compared with the strategy that would have been proposed in case of PET not available and/or not strictly indicated, accordin…

Malemedicine.medical_specialtyRadical treatmentmedicine.medical_treatmentClinical Decision-Making18F-cholineMultimodal ImagingCholineAndrogen deprivation therapyProstate cancerProstateNuclear Medicine and ImagingIntensity-ModulatedMedicineHumansRadiology Nuclear Medicine and imagingRadiation treatment planningTomographyAgedPET-CTProstate cancerRadiotherapybusiness.industryCancerProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseX-Ray ComputedRadiation therapymedicine.anatomical_structurePositron-Emission TomographyRadiologyCho-PET/CT; Prostate cancer; Radical treatment; Radiotherapy; Aged; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Prostatic Neoplasms; Radiopharmaceuticals; Clinical Decision-Making; Positron-Emission Tomography; Radiotherapy Intensity-Modulated; Tomography X-Ray Computed; Radiology Nuclear Medicine and ImagingRadiotherapy Intensity-ModulatedRadiopharmaceuticalsbusinessNuclear medicineRadiologyTomography X-Ray ComputedCho-PET/CT
researchProduct

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prosta…

2017

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signi…

Malemedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentUrologyAbiraterone AcetateBone NeoplasmsAbiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and GerontologyPlaceboDisease-Free Survivallaw.invention03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineRandomized controlled triallawNitrilesPhenylthiohydantoinEnzalutamideAndrogen Receptor AntagonistsMedicineEnzalutamideCytochrome P-450 Enzyme InhibitorsHumans030212 general & internal medicineProgression-free survivalAbirateronetSRERandomized Controlled Trials as TopicChemotherapybusiness.industryAbiraterone acetateHematologymCRPCmedicine.diseaseProstatic Neoplasms Castration-ResistantTreatment OutcomechemistryDocetaxelrPFSOncology030220 oncology & carcinogenesisBenzamidesDisease ProgressionGeriatrics and Gerontologybusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Computer-Aided Detection for Prostate Cancer Detection based on Multi-Parametric Magnetic Resonance Imaging

2017

International audience; Prostate cancer (CaP) is the second most diagnosed cancer in men all over the world. In the last decades, new imaging techniques based on magnetic resonance imaging (MRI) have been developed improving diagnosis. In practice, diagnosis is affected by multiple factors such as observer variability and visibility and complexity of the lesions. In this regard, computer-aided detection and diagnosis (CAD) systems are being designed to help radiologists in their clinical practice. We propose a CAD system taking advantage of all MRI modalities (i.e., T2-W-MRI, DCE-MRI, diffusion weighted (DW)-MRI, MRSI). The aim of this CAD system was to provide a probabilistic map of cancer…

Malemedicine.medical_specialtySource codemedia_common.quotation_subject[INFO.INFO-IM] Computer Science [cs]/Medical ImagingContrast MediaCAD[ SPI.SIGNAL ] Engineering Sciences [physics]/Signal and Image processing030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicine[STAT.ML]Statistics [stat]/Machine Learning [stat.ML]Prostatemedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumans[ STAT.ML ] Statistics [stat]/Machine Learning [stat.ML][SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processingmedia_commonMulti parametricModality (human–computer interaction)[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsCancerMagnetic resonance imagingmedicine.diseaseMagnetic Resonance Imaging[STAT.ML] Statistics [stat]/Machine Learning [stat.ML]3. Good healthmedicine.anatomical_structureRadiologybusiness[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing030217 neurology & neurosurgery
researchProduct